Teva Pharmaceutical Industries ADR
(TEVA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 17,258,000 | 16,544,000 | 15,846,000 | 14,925,000 | 15,878,000 |
| Cost of Goods | 8,320,000 | 8,481,000 | 8,200,000 | 7,952,000 | 8,284,000 |
| Gross Profit | 8,938,000 | 8,064,000 | 7,645,000 | 6,973,000 | 7,594,000 |
| Operating Expenses | 6,780,000 | 7,086,000 | 7,213,000 | 9,170,000 | 5,879,000 |
| Operating Income | 2,158,000 | 977,000 | 433,000 | -2,197,000 | 1,715,000 |
| Other Income | -920,000 | -2,260,000 | -1,055,000 | -945,000 | -1,048,000 |
| Pre-tax Income | 1,238,000 | -1,283,000 | -622,000 | -3,142,000 | 667,000 |
| Income Tax | -180,000 | 676,000 | -7,000 | -643,000 | 211,000 |
| Net Income Continuous | 1,418,000 | -1,959,000 | -615,000 | -2,499,000 | 456,000 |
| Minority Interests | 7,000 | -320,000 | -56,000 | -53,000 | 39,000 |
| Net Income | $1,411,000 | $-1,639,000 | $-559,000 | $-2,446,000 | $417,000 |
| EPS Basic Total Ops | 1.23 | -1.45 | -0.50 | -2.20 | 0.38 |
| EPS Basic Continuous Ops | 1.24 | -1.73 | -0.55 | -2.25 | 0.41 |
| EPS Diluted Total Ops | 1.21 | -1.45 | -0.50 | -2.20 | 0.38 |
| EPS Diluted Continuous Ops | 1.22 | -1.73 | -0.55 | -2.25 | 0.41 |
| EPS Diluted Before Non-Recurring Items | 2.82 | 2.40 | 2.46 | 2.42 | 2.48 |
| EBITDA(a) | $3,160,000 | $2,036,000 | $1,586,000 | $-889,000 | $3,045,000 |